IGHE and atopic eczema: The proven efficacy of dupilumab in atopic dermatitis and other type 2 diseases not necessarily associated with elevation of IgE level, including chronic rhinosinusitis with nasal polyps and eosinophilic esophagitis, and its favorable safety profile, were important considerations in our decision to institute dupilumab therapy, which turned out to be very effective for our patient.7